

Ethan B. Russo · John M. McPartland

Cannabis is more than simply Δ^9 -tetrahydrocannabinol

Received: 13 August 2002 / Accepted: 30 October 2002 / Published online: 19 December 2002
© Springer-Verlag 2002

In response to your recent publication comparing subjective effects of Δ^9 -tetrahydrocannabinol and herbal cannabis (Wachtel et al. 2002), a number of comments are necessary. The first concerns the suitability of the chosen “marijuana” to assay the issues at hand. NIDA cannabis has been previously characterized in a number of studies (Chait and Pierri 1989; Russo et al. 2002), as a crude low-grade product (2–4% THC) containing leaves, stems and seeds, often 3 or more years old after processing, with a stale odor lacking in terpenoids. This contrasts with the more customary clinical cannabis employed by patients in Europe and North America, composed solely of unseeded flowering tops with a potency of up to 20% THC. Cannabis-based medicine extracts (CBME) (Whittle et al. 2001), employed in clinical trials in the UK (Notcutt 2002; Robson et al. 2002), are extracted from flowering tops with abundant glandular trichomes, and retain full terpenoid and flavonoid components.

In the study at issue (Wachtel et al. 2002), we are informed that marijuana contained 2.11% THC, 0.30% cannabinal (CBN), and 0.05% (CBD). The concentration of the latter two cannabinoids is virtually inconsequential. Thus, we are not surprised that no differences were seen between NIDA marijuana with essentially only one cannabinoid, and pure, synthetic THC. In comparison, clinical grade cannabis and CBME customarily contain high quantities of CBD, frequently equaling the percentage of THC (Whittle et al. 2001).

Carlini et al. (1974) determined that cannabis extracts produced effects “two or four times greater than that expected from their THC content, based on animal and human studies”. Similarly, Fairbairn and Pickens (1981) detected the presence of unidentified “powerful syner-

gists” in cannabis extracts, causing 330% greater activity in mice than THC alone.

The clinical contribution of other CBD and other cannabinoids, terpenoids and flavonoids to clinical cannabis effects has been espoused as an “entourage effect” (Mechoulam and Ben-Shabat 1999), and is reviewed in detail by McPartland and Russo (2001). Briefly summarized, CBD has anti-anxiety effects (Zuardi et al. 1982), anti-psychotic benefits (Zuardi et al. 1995), modulates metabolism of THC by blocking its conversion to the more psychoactive 11-hydroxy-THC (Bornheim and Grillo 1998), prevents glutamate excitotoxicity, serves as a powerful anti-oxidant (Hampson et al. 2000), and has notable anti-inflammatory and immunomodulatory effects (Malfait et al. 2000).

Terpenoid cannabis components probably also contribute significantly to clinical effects of cannabis and boil at comparable temperatures to THC (McPartland and Russo 2001). Cannabis essential oil demonstrates serotonin receptor binding (Russo et al. 2000). Its terpenoids include myrcene, a potent analgesic (Rao et al. 1990) and anti-inflammatory (Lorenzetti et al. 1991), beta-caryophyllene, another anti-inflammatory (Basile et al. 1988) and gastric cytoprotective (Tambe et al. 1996), limonene, a potent inhalation antidepressant and immune stimulator (Komori et al. 1995) and anti-carcinogenic (Crowell 1999), and alpha-pinene, an anti-inflammatory (Gil et al. 1989) and bronchodilator (Falk et al. 1990).

Are these terpenoid effects significant? A dried sample of drug-strain cannabis buds was measured as displaying an essential oil yield of 0.8% (Ross and ElSohly 1996), or a putative 8 mg per 1000 mg cigarette. Buchbauer et al. (1993) demonstrated that 20–50 mg of essential oil in the ambient air in mouse cages produced measurable changes in behavior, serum levels, and bound to cortical cells. Similarly, Komori et al. (1995) employed a gel of citrus fragrance with limonene to produce a significant antidepressant benefit in humans, obviating the need for continued standard medication in some patients, and also improving CD4/8 immunologic ratios. These data would

E. B. Russo (✉)
Montana Neurobehavioral Specialists,
900 North Orange Street, Missoula, MT, 59802 USA
e-mail: erusso@blackfoot.net

J. M. McPartland
Faculty of Health and Environmental Science,
UNITEC,
Private Bag 92025, Mt Albert, Auckland, New Zealand

strongly support a demonstrable clinical role for cannabis terpenoids.

Flavonoid components of cannabis, especially likely to be of benefit in oral or sublingual administration, include apigenin, a unique agent that has strong anti-anxiety effects without sedation (Salgueiro et al. 1997).

Finally, although anecdotal, this author (E.B.R.) has had the opportunity to interview an estimated 200 patients who have employed Marinol and clinical cannabis, whether smoked or ingested. In no instance were the effects of the former considered of equal efficacy to cannabis, but rather more productive of dysphoric and sedative adverse effects (Calhoun et al. 1998).

In essence, clinical cannabis demonstrates herbal synergy and is more than a simply a vehicle for THC administration.

References

- Basile AC, Sertie JA, Freitas PC, Zanini AC (1988) Anti-inflammatory activity of oleoresin from Brazilian *Copaifera*. *J Ethnopharmacol* 22:101–109
- Bornheim LM, Grillo MP (1998) Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. *Chem Res Toxicol* 11:1209–1216
- Buchbauer G, Jirovetz L, Jager W, Plank C, Dietrich H (1993) Fragrance compounds and essential oils with sedative effects upon inhalation. *J Pharm Sci* 82:660–664
- Calhoun SR, Galloway GP, Smith DE (1998) Abuse potential of dronabinol (Marinol). *J Psychoact Drugs* 30: 187–196
- Carlini EA, Karniol IG, Renault PF, Schuster CR (1974) Effects of marijuana in laboratory animals and man. *Br J Pharmacol* 50:299–309
- Chait LD, Pierri J (1989) Some physical characteristics of NIDA marijuana cigarettes. *Addict Behav* 14:61–67
- Crowell PL (1999) Prevention and therapy of cancer by dietary monoterpenes. *J Nutr* 129:775S–778S
- Falk AA, Hagberg MT, Lof AE, Wigaeus-Hjelm EM, Wang ZP (1990) Uptake, distribution and elimination of alpha-pinene in man after exposure by inhalation. *Scand J Work Environ Health* 16:372–378
- Fairbairn JW, Pickens JT (1981) Activity of Cannabis in relation to its Δ^1 -tetrahydrocannabinol content. *Br J Pharmacol* 72:401–409
- Gil ML, Jimenez J, Ocete MA, Zarzuelo A, Cabo MM (1989) Comparative study of different essential oils of *Bupleurum gibraltaricum* Lamarck. *Pharmazie* 44:284–287
- Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J (2000) Neuroprotective antioxidants from marijuana. *Ann NY Acad Sci* 899:274–282
- Komori T, Fujiwara R, Tanida M, Nomura J, Yokoyama MM (1995) Effects of citrus fragrance on immune function and depressive states. *Neuroimmunomodulation* 2:174–180
- Lorenzetti BB, Souza GE, Sarti SJ, Santos Filho D, Ferreira SH (1991) Myrcene mimics the peripheral analgesic activity of lemongrass tea. *J Ethnopharmacol* 34:43–48
- Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritis therapeutic in murine collagen-induced arthritis. *Proc Natl Acad Sci USA* 97:9561–9566
- McPartland JM, Russo EB (2001) Cannabis and cannabis extracts: greater than the sum of their parts? *J Cannabis Ther* 1:103–132
- Mechoulam R, Ben-Shabat S (1999) From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. *Nat Prod Rep* 16:131–143
- Notcutt W (2002) Medicinal cannabis extracts in chronic pain. *J Cannabis Ther* 2:101–102
- Rao VS, Menezes AM, Viana GS (1990) Effect of myrcene on nociception in mice. *J Pharm Pharmacol* 42:877–878
- Robson PJ, Wade DT, Makela PM, House H (2002) Cannabis medicinal extracts (CME), including cannabidiol, alleviated neurogenic symptoms in patients with multiple sclerosis and spinal cord injury. Symposium on the Cannabinoids. International Cannabinoid Research Society, Asilomar Conference Center, Pacific Grove, Calif., p 56
- Ross SA, ElSohly MA (1996) The volatile oil composition of fresh and air-dried buds of *Cannabis sativa*. *J Nat Prod* 59:49–51
- Russo E, Macarah CM, Todd CL, Medora RS, Parker KK (2000) Pharmacology of the essential oil of hemp at 5HT1A and 5HT2a receptors. 41st Annual Meeting of the American Society of Pharmacognosy. *J Nat Prod*
- Russo EB, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, Kirlin KA (2002) Chronic cannabis use in the Compassionate Investigational New Drug Program: an examination of benefits and adverse effects of legal clinical cannabis. *J Cannabis Ther* 2:3–57
- Salgueiro JB, Ardenghi P, Dias M, Ferreira MB, Izquierdo I, Medina JH (1997) Anxiolytic natural and synthetic flavonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats. *Pharmacol Biochem Behav* 58:887–91
- Tambe Y, Tsujiuchi H, Honda G, Ikeshiro Y, Tanaka S (1996) Gastric cytoprotection of the non-steroidal anti-inflammatory sesquiterpene, beta-caryophyllene. *Planta Med* 62:469–70
- Wachtel SR, ElSohly MA, Ross RA, Ambre J, de Wit H (2002) Comparison of the subjective effects of delta9-tetrahydrocannabinol and marijuana in humans. *Psychopharmacology* 161:331–339
- Whittle BA, Guy GW, Robson P (2001) Prospects for new cannabis-based prescription medicines. *J Cannabis Ther* 1:183–205
- Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. *Psychopharmacology* 76:245–250
- Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R (1995) Antipsychotic effect of cannabidiol. *J Clin Psychiatry* 56:485–486